StockData
Adial Pharmaceuticals, Inc. logo

Adial Pharmaceuticals, Inc. (AZR) stock

AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$9.74M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$57.80M
EPS, diluted
-$11.93
Book value per share
-$8.30
Diluted shares
5M

Trading

Beta (5 years)
0.81
52-week range
$1.31 – $9.50
RSI (14 days)
44.5
Volatility (1 year)
102.9%
Relative volume
0.13×
WACC
9.0%

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Operating income

-$57.68M

Net income

-$57.80M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Adial Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Adial Pharmaceuticals

Pharmaceutical Preparations

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment or prevention of addiction and related disorders. Its primary investigational drug candidate is AD04, a therapeutic agent designed to treat alcohol use disorder (AUD). The company develops this treatment alongside a companion diagnostic genetic test to identify and target patients with specific genotypes. Adial has no approved products and focuses its resources on research, development, and clinical evaluation.

Company profile, executives and history

Adial Pharmaceuticals stock: common questions

What is AZR's P/E ratio?

Adial Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$11.93), so it has no meaningful P/E ratio.

Does Adial Pharmaceuticals pay a dividend?

No. Adial Pharmaceuticals has not paid a cash dividend over the last twelve months.

How many AZR shares are sold short?

0M shares were sold short at the latest FINRA report, 10.26% of the float, or 4.3 days of average trading volume.

Who are Adial Pharmaceuticals's competitors?

Companies most similar to Adial Pharmaceuticals by business, industry and size include ANL, ALT, ADXN, GHRS, CING.